Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1905928 | 1.00 | HSD17B10 (0.59) | HSD17B10CYP1A2CYP2C19TDP1PKM | |
| SCHEMBL19810725 | 0.87 | SLC6A3 (0.47) | HSD17B10CYP1A2CYP2C19TDP1PKM | |
| SCHEMBL17978184 | 0.87 | SLC6A3 (0.47) | HSD17B10CYP1A2CYP2C19TDP1PKM | |
| SCHEMBL9000294 | 0.86 | TDP1 (0.51) | HSD17B10CYP1A2CYP2C19TDP1PKM | |
| SCHEMBL1905601 | 0.84 | KDM4E (0.52) | HSD17B10CYP1A2CYP2C19TDP1PKM | |
| SCHEMBL1905604 | 0.84 | KDM4E (0.52) | HSD17B10CYP1A2CYP2C19TDP1PKM | |
| SCHEMBL4469339 | 0.81 | SIRT2 (0.50) | HSD17B10CYP1A2CYP2C19TDP1PKM | |
| SCHEMBL4469336 | 0.81 | SIRT2 (0.50) | HSD17B10CYP1A2CYP2C19TDP1PKM | |
| SCHEMBL4556787 | 0.79 | TDP1 (0.54) | HSD17B10TDP1PKML3MBTL1POLB | |
| SCHEMBL4061684 | 0.78 | NPC1 (0.54) | CYP1A2CYP2C19PKML3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335726-B1 | MODIFIED PRODRUG FORMS OF AP | NANOTHERAPEUTICS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-100544718-C | Use of compounds in the preparation of antiviral agents | VION PHARMACEUTICALS INC YALE (US) | 2009-09-30 | — | — | CN | disclosed |
| EP-1335726-A4 | MODIFIED PRODRUG FORMS OF AP/AMP | VION PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20050261251-A1 | Antiviral agents and methods of treating viral infections | VION PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| CN-1224388-C | Modified prodrug forms of ap/amp | VION PHARMACEUTICALS INC (US) | 2005-10-26 | — | — | CN | disclosed |
| US-6911460-B2 | Antiviral agents and methods of treating viral infections | VION PHARMACEUTICALS, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| CN-1503669-A | Antiviral agents and methods of treating viral infections | ά�¶�ҩƷ��˾ | 2004-06-09 | — | — | CN | disclosed |
| CN-1468102-A | Modified prodrug forms of ap/amp | ά�¶�ҩƷ��˾ | 2004-01-14 | — | — | CN | disclosed |
| EP-1335726-A1 | MODIFIED PRODRUG FORMS OF AP/AMP | Vion Pharmaceuticals, Inc. (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-12 | — | — | US | disclosed |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | NANOTHERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002030424-A1 | MODIFIED PRODRUG FORMS OF AP/AMP | VION PHARMACEUTICALS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| EP-0277661-B1 | IMIDAZOPYRROLOPYRIDINES AND CONDENSED DERIVATIVES THEREOF USEFUL IN THE PREPARATION OF HERBICIDAL COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 1992-09-16 | — | — | EP | disclosed |
| EP-0133309-B1 | HERBICIDES AND METHOD FOR THE PREPARATION THEREOF | AMERICAN CYANAMID COMPANY (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0133310-B1 | IMIDAZOLIDINONES, AND IMIDAZOLIDINETHIONES, PROCESS FOR THE PREPARATION THEREOF, AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | AMERICAN CYANAMID COMPANY (US) | 1988-09-14 | — | — | EP | disclosed |
| EP-0277661-A1 | Imidazopyrrolopyridines and condensed derivatives thereof useful in the preparation of herbicidal compounds | AMERICAN CYANAMID COMPANY (US) | 1988-08-10 | — | — | EP | disclosed |
| US-4701208-A | Dihydroimidazopyrrolopyridine, quinoline, thieno- and furo[2,3-b]pyridine, dihydrothieno- and furo[2,3-b]-pyridine, thieno- and furo[3,2-b]pyridine and dihydrothieno- and furo[3,2-b]pyridine herbicides and method for preparation thereof | AMERICAN CYANAMID COMPANY (US) | 1987-10-20 | — | — | US | disclosed |
| US-4608079-A | Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1986-08-26 | — | — | US | disclosed |
| EP-0133310-A1 | Imidazolidinones, and imidazolidinethiones, process for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
| EP-0133309-A1 | Herbicides and method for the preparation thereof | AMERICAN CYANAMID COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | AMPD3, AMPD2, MTAP | HSD17B10 3386/4885CYP1A2 1144/4885CYP2C19 1997/4885 |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | AP3B1, AP3D1, AP3M1 | HSD17B10 2955/4885CYP1A2 2512/4885CYP2C19 2588/4885 |
| US-20050261251-A1 | Antiviral agents and methods of treating viral infections | AMPD3, AMPD2, MTAP | HSD17B10 3386/4885CYP1A2 1144/4885CYP2C19 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.